NCT06556641View on ClinicalTrials.gov

A Clinical Study of GZR33 and GZR101 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

December 17, 2022

Primary Completion Date

February 3, 2023

Study Completion Date

February 3, 2023

Conditions
Healthy Subjects
Interventions
DRUG

GZR33 Injection

Administered as once daily subcutaneous dose

DRUG

GZR101 Injection

Administered as once daily subcutaneous dose

DRUG

Placebo

Administered as once daily subcutaneous dose

DRUG

Insulin Degludec

Administered as once daily subcutaneous dose

Trial Locations (1)

Unknown

Study Site, Xingtai

Sponsors
All Listed Sponsors
lead

Gan and Lee Pharmaceuticals, USA

INDUSTRY